Novartis has reported positive 5-year efficacy and safety results for Cosentyx from a phase 3 long-term extension study in patients with moderate-to-severe plaque psoriasis.
Data from the study will be presented at a medical congress in the second half of 2017, according to a news release.
No commercial support for this activity.
American Association of Nurse Practitioners National Conference
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
©2017 Healio All Rights Reserved.